Literature DB >> 11833633

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Laurence L Greenhill, Steven Pliszka, Mina K Dulcan, William Bernet, Valerie Arnold, Joseph Beitchman, R Scott Benson, Oscar Bukstein, Joan Kinlan, Jon McClellan, David Rue, Jon A Shaw, Saundra Stock.   

Abstract

This practice parameter describes treatment with stimulant medication. It uses an evidence-based medicine approach derived from a detailed literature review and expert consultation. Stimulant medications in clinical use include methylphenidate, dextroamphetamine, mixed-salts amphetamine, and pemoline. It carries FDA indications for treatment of attention-deficit/hyperactivity disorder and narcolepsy.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11833633     DOI： 10.1097/00004583-200202001-00003

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN： 0890-8567            Impact factor:   8.829


  170 in total

1.  Methylphenidate transdermal system in adults with past stimulant misuse: an open-label trial.

Authors:  Aimee L McRae-Clark; Kathleen T Brady; Karen J Hartwell; Kathleen White; Rickey E Carter
Journal:  J Atten Disord       Date:  2010-06-10       Impact factor: 3.256

2.  The relationship between past-year drinking behaviors and nonmedical use of prescription drugs: prevalence of co-occurrence in a national sample.

Authors:  Sean Esteban McCabe; James A Cranford; Carol J Boyd
Journal:  Drug Alcohol Depend       Date:  2006-04-18       Impact factor: 4.492

3.  Methylphenidate enhances prepulse inhibition during processing of task-relevant stimuli in attention-deficit/hyperactivity disorder.

Authors:  Rebecca L Ashare; Larry W Hawk; Keri Shiels; Jessica D Rhodes; William E Pelham; James G Waxmonsky
Journal:  Psychophysiology       Date:  2010-03-10       Impact factor: 4.016

Review 4.  Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.

Authors:  Timothy E Wilens; Thomas J Spencer
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

5.  Use of psychotropic medication guidelines at child-serving community mental health centers as assessed by clinic directors.

Authors:  Jack Stevens; Kelly J Kelleher; Wei Wang; Sonja K Schoenwald; Kimberly E Hoagwood; John Landsverk
Journal:  Community Ment Health J       Date:  2010-09-29

Review 6.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

7.  Acute and sub-chronic functional neurotoxicity of methylphenidate on neural networks in vitro.

Authors:  K V Gopal; B R Miller; G W Gross
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

8.  Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Authors:  John S Markowitz; Arthur B Straughn; Kennerly S Patrick; C Lindsay DeVane; Linda Pestreich; James Lee; Yanfeng Wang; Rafael Muniz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Assessment and management of attention-deficit hyperactivity disorder in adults.

Authors:  Margaret Weiss; Candice Murray
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

10.  Participant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Authors:  Ann C Childress; Andrew J Cutler; Keith Saylor; Maria Gasior; Mohamed Hamdani; M Celeste Ferreira-Cornwell; Robert L Findling
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05-09       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.